Target-specific drugs (e.g. Vemurafenib, Dabrafenib) were developed and initially approved for the treatment of BRAF V600E mutant melanomas, and have since been trialled first in malignant, and more recently in low-grade BRAF V600E mutant brain tumours [1, 35]. Here, BRAF is linked to brain neoplasm.